The mechanisms by which interferon-alpha (IFN-alpha) restores normal hematopoiesis in chronic myelogenous leukemia (CML) are not well understood. We have recently demonstrated that IFN-alpha acts directly on CML hematopoietic progenitors to restore their adhesion to marrow stroma by modulating beta 1 integrin receptor function. In the present study we examined the effect of IFN-alpha treatment of marrow stroma on subsequent adhesion of CML progenitors. Stromal layers were preincubated with IFN-alpha (10,000 microns/ml) for 48 h. Subsequent coincubation with CML progenitors for 2 h resulted in significantly increased adhesion of CML progenitors. We demonstrated that alpha 4 beta 1 and alpha 5 beta 1 integrin receptors were involved in the enhanced adhesion of CML progenitors, suggesting that IFN-alpha-treated stroma can upregulate CML integrin function. This effect is due, at least in part, to IFN-alpha-induced increased stromal production of the chemokine macrophage inflammatory protein-1 alpha (MIP-1 alpha), which upregulates beta 1 integrin-dependent adhesion of CML progenitors to stroma. Thus, IFN-alpha treatment of marrow stroma restores beta 1 integrin-dependent adhesion of CML progenitors, at least in part through induction of MIP-1 alpha production. These observations provide further insights into mechanisms by which IFN-alpha may restore normal hematopoiesis in CML.
Introduction
Chronic myelogenous leukemia (CML)1 is characterized by a 1. Abbreviations used in this paper: BMMNC, bone marrow mononuclear cell; CFC, colony-forming cells; CML, chronic myelogenous leukemia; LTC-IC, long term culture-initiating cells; LTBMC, long-term bone marrow culture; MIP, macrophage inflammatory protein; VCAM, vascular cell adhesion molecule. nant bcr/abl positive clone, resulting from unregulated proliferation of malignant hematopoietic progenitors ( 1) . We, and others, have demonstrated that direct contact between normal progenitors and stroma is important for negative regulation of progenitor growth (2, 3) . Normal primitive hematopoietic progenitors are usually quiescent when present in close contact with marrow stroma (2) and proliferate significantly more when cultured separated from stroma by a transwell which prevents direct progenitor-stroma contact than when cultured in contact with stroma (3) . This may be the result of juxtacrine effects of stroma-bound growth inhibitory cytokines, such as TGF-,l3
and macrophage inflammatory protein-la (MIP-la) (4) (5) (6) (7) . More recently, we demonstrated that inhibition of progenitor proliferation may also be the result of transduction of growth inhibitory signals subsequent to the engagement of integrin adhesion receptors on progenitors by their stromal ligands (8) . Unlike normal progenitors, CML progenitors are continuously proliferating, even when in close contact with stromal layers. The abnormal proliferation of CML progenitors may be related to the abnormal adhesive interactions between CML progenitors and the marrow stromal microenvironment (9, 10) .
Normal progenitors adhere to stroma through a variety of cell surface adhesion receptors, including a4P1 integrin receptors, which bind to vascular cell adhesion molecule (VCAM) and the CS-1 region in the COOH-terminal heparin-binding domain of fibronectin, and a5/31 integrin receptors, which bind to the RGD-containing cell-binding domain of fibronectin (11) (12) (13) (14) (15) . Compared with normal progenitors, CML progenitors show reduced adhesion to stromal layers as well as to fibronectin and its proteolytic fragments (9, 16 ). However, a4p31 and a5,61 integrin receptors are expressed at normal levels on CML progenitors, suggesting that the function of these receptors is impaired in CML (9, 10) .
IFN-a can induce hematologic remissions in up to 75% of patients with chronic myelogenous leukemia and can induce complete cytogenetic remissions in a smaller number of patients with gradual, selective suppression of the malignant clone and restoration of normal hematopoiesis (17) . The mechanisms by which IFN-a restores normal hematopoiesis in CML are not clear. One possibility is that IFN-a acts by correcting the defective adhesion of CML progenitors to marrow stroma, which may in turn result in restoration of normal microenvironmental regulation of progenitor proliferation. We have recently demonstrated that treatment of CML progenitors with LFN-a results in their enhanced adhesion to marrow stroma as a result of modulation of a4,f1 and a5/31 integrin receptor function (10).
Upadhyaya et al. have demonstrated that incubation with IFNa also restores the deficient expression of LFA-3 on CML progenitor cells (18) . IFN-a may also affect adhesion of CML progenitors through effects on the marrow microenvironment besides its direct effects on CML progenitors. Dowding et al. demonstrated that culture of marrow stroma in the presence of IFN-a followed by co-culture of CML progenitors in the continued presence of IFN-a resulted in enhanced adhesion of CML progenitors to stroma (19) . However, the mechanisms underlying the increased adhesion of CML progenitors under these conditions were not clear. It is possible that, aside from upregulating the expression of adhesion receptors on hematopoietic progenitors, IEN-a may act through upregulating the expression of ligands for adhesion receptors on stromal cells (20) , as is well described for IFN-'y (21, 22) . Alternatively, IFN-a may alter the composition of stromal extracellular matrix (23) or induce the production of other cytokines by stromal cells, which in turn may alter adhesive interactions between progenitors and stroma. In the present study, we examined the effect of IFN-a treatment of marrow stroma on the subsequent adhesion of CML progenitors. CML progenitors demonstrated significantly enhanced adhesion to IFN-a pretreated stroma as compared with untreated stroma. Increased adhesion was mediated by a4f31 and aS,/1 integrin adhesion receptors, suggesting that IFN-atreated stroma can restore integrin-mediated adhesion mechanisms in CML. We provide evidence that increased production of MWP-la by IFN-a-treated stroma may play a role in the enhanced f31 integrin-mediated adhesion of CML progenitors.
Methods
Bone marrow samples 26 patients with CML and 5 normal healthy volunteers were evaluated after informed consent was obtained using guidelines approved by the Committee on the Use of Human Subjects at the University of Minnesota. All patients were in the chronic phase of CML. 2 patients were untreated at the time 6f study. 24 patients were receiving treatment with Hydroxyurea alone, which was discontinued at least 4 d before the study. Of the Hydroxyurea-treated patients, 5 had been previously treated with lFN-a, which had been discontinued at least 3 mo prior to the study.
Heparinized bone marrow samples were obtained by aspiration from the posterior iliac crest. Bone marrow mononuclear cells (BMMNC) were isolated using Ficoll-Hypaque (Sigma Chemical Co., St. Louis, MO) density gradient separation (specific gravity 1.077) for 30 min at 37°C and 400 g.
Selection ofpurified progenitor populations
Selection of purified progenitor populations was performed using methods previously described (24, 25). Lineage-negative cells were obtained from CML or normal BMMNC by sequential counterflow centrifugation elutriation (26) , sheep erythrocyte rosetting (27) and immunomagnetic bead depletion (24, 25 for the presence of CFU-GM, BFU-E and CFU-MIX colonies, as previously described (27).
Measurement of MIP-Ja production by IFN-a -treated stromal layers
Normal stromal layers grown in 24-well plates were incubated with IFNa (10,000 U/ml) for varying periods of time, after which the supernatant media was collected, aliquoted, and stored at -800C until analysis for MIP-la was carried out by standard, commercially available ELISA assay kits (R & D Systems, Inc.). For measuring the MIP-la content of the stromal layers themselves, layers were washed three times and then detached using non-enzymatic stroma lysis solution (Sigma). Cells were pelleted, mixed with 1 ml of cell lysis solution (25 mM Tris-HCl, 150 mM NaCl, with 1% Triton-X 100, supplemented with 1 mM PMSF) for 20 min, and centrifuged at 20,000 g for 10 min, after which the supernatant medium (protein extract) was collected and assayed for MIP-la levels by ELISA.
Cytogenetic analysis ofplucked colonies
Colonies were plucked from methylcellulose progenitor cultures initiated with CML CD34+HLA-DR+ cells harvested from either the adherent or nonadherent fractions from adhesion assays on IFN-a-treated stromal layers. Colonies resulting from either the adherent or nonadherent fractions were pooled and subjected to a 1.5-h colcemid incubation followed by lysis with hypotonic KCl and fixation with acetic acid/ methyl alcohol as previously described. Metaphases were then analyzed by QFQ and GTG banding (28 compared with normal CFC. However, IFN-a treatment of stromal layers before the adhesion assays resulted in significantly increased adhesion of CML LTC-IC (P < 0.001, n = 5) as well as more committed CML progenitors (BFU-E, P < 0.001, n = 18; CFU-GM, P < 0.001, n = 18; and CFU-MIX, P < 0.001, n = 14). (Fig. ina) . In contrast, adhesion of normal bone marrow-derived LTC-IC and CFU-MIX was not significantly increased after the stroma was treated with IFN-a, while adhesion of normal BFU-E and CFU-GM was slightly, although significantly, increased (BFU-E, P = 0.053; CFU-GM, P = 0.006, n = 5) (Fig. 1 b) . Altered Adhesion of CML progenitors to IFN-a-treated stroma was IFN-a concentration dependent (Fig. 2) . Interestingly, adhesion of CML LTC-IC to stroma treated with as low a concentration of IFN-a as 100 U/ml was no longer significantly different than the adhesion of normal LTC-IC to stroma (Fig. 2) . Furthermore, increasing the length of exposure of stroma to IFN-a prior to the adhesion assays resulted in progressively increased adhesion of CML progenitors (Fig. 3) .
Role of /31 integrin receptors in the adhesion of CML progenitors to IFN-a -treated marrow stroma. To characterize the receptors on CML progenitors responsible for the enhanced adhesion to IFN-a-treated stroma, we examined the ability of antibodies directed against integrin receptors, CD44, VCAM, or ICAM to block the adhesion. CML DR+ cells were allowed to adhere to IFN-a-treated, washed stromal layers for 2 h in the presence of antibodies against a4, a5, /1, CD44, VCAM, and ICAM-1. The adhesion of CML CFC to stroma that was not pretreated with IFN-a was not significantly inhibited by these antibodies (BFU-E: control adhesion, 25.9±4.8%; with anti-a4, 25.6±5.6%; anti-a5, 25.8±+4.8%; anti-#1, 20 anti-VCAM, 25.4±2.5%; n = 4). However, adhesion of CML BFU-E and CFU-GM to IFN-a-treated stroma was significantly inhibited by antibodies against a4 (P < 0.05), a5 (P < 0.05), and /31 (P < 0.05) integrin receptors as well as VCAM (P < 0.05, n = 5) (Fig. 4) Role ofincreased MIP-Ia production in enhanced adhesion of CML progenitors to IFN-a -treated stroma. Because members of the chemokine family are capable of increasing /81 integrin-dependent adhesion (29, 30) , we investigated whether MIP-la was a secondary mediator in the enhanced adhesion of CML progenitors to IFN-a-treated stroma. We examined the effect of IFN-a on MIP-la production by marrow stroma. IFNa treatment (10,000 U/ml) of stroma resulted in sixfold higher levels of MIP-la in stromal lysates (Fig. 5) . Similarly, IFN-a treatment resulted in 1.5-to 2-fold higher levels of MIP-1a in stromal supernatants (n = 4; data not shown).
To correlate IFN-a-induced increased MIP-la production with the increase in CML progenitor adhesion, we studied the effect of neutralizing antibodies against MIP-la on the adhesion of CML progenitors to IFN-a-treated stroma. Anti-MIP-la antibodies significantly reduced the adhesion of CML CFU-GM ( Fig. 6 ) and BFU-E (not shown). These results indicate that increased adhesion of CML progenitors to IFN-a-treated stroma was at least due in part to increased stromal production of MIP-1a. This was confirmed in experiments in which increasing concentrations of MIP-la were added during the adhesion assays between CML progenitors and stromal layers that had not been exposed to IFN-a. Addition of MIP-la for the 2 h of the assay resulted in increased adhesion of CML CFU-GM (Fig. 7) and BFU-E (not shown) to stroma in a concentrationdependent manner.
Finally, we studied the role of /31 integrins in MIP-lainduced adhesion of CML progenitors to stroma by examining the ability of anti-,/1 integrin antibodies to block the adhesion of MIP-la-pretreated CML progenitors to stroma ( Fig. 8; BFU-E not shown). As we demonstrated earlier, anti-,31 antibodies did not inhibit the adhesion of untreated CML progenitors. However, pretreatment of progenitors with MIP-la (10 ng/ml for 2 h) before performing the adhesion assay increased their adhesion to stroma not treated with IPN-a. The increased adhesion of CML progenitors induced by MmP-la pretreatment could be blocked with anti-,31 antibodies, indicating that the MIP-la-induced adhesion of CML progenitors to stroma is /1 integrin dependent.
Discussion
Treatment of CML patients with IFN-a can result in selective suppression of malignant hematopoiesis and resumption of normal hematopoiesis (17) . The mechanism by which IFN-a achieves this effect is not well understood. We hypothesized that IFN-a restores important mechanisms of microenvironmental regulation of hematopoietic progenitor proliferation defective in CML. In previous studies, we have shown that IFN-a directly enhances CML progenitor adhesion to stroma through upregulation of 3il integrin receptor function (3) . In this study, we show that IFN-a treatment of marrow stroma can also lead to enhanced adhesion of CML progenitors through /1 integrinmediated mechanisms. We demonstrate that increased stromal production of MIP-la may, at least in part, be responsible for b. upregulation of p1 integrin function on CML progenitors exposed to IFN-a-treated stroma. the increased adhesion of CML progenitors to IFN-atreated stroma is not caused by residual stroma-bound IFN-a, since enhanced adhesion of CML progenitors following direct incubation with IFN-a requires at least a 12-h exposure (3) . No significant increase in progenitor adhesion was seen when CML progenitors were exposed to IFN-a for only 2 h, which was the duration of the adhesion assay used here. Therefore, we hypothesized that secondary events resulting from IFN-a preincubation must be responsible for enhanced p1 integrinmediated adhesion of CML progenitors. IFN-a is likely to have multiple effects on stromal cells, including stimulation of cytokine production and altered expression of ECM components and cell surface adhesion receptors (20, 23) . Two recent studies have demonstrated that members of the chemokine family of cytokines can influence integrin-mediated adhesion. MLP-1l, a member of this family, in conjunction with proteoglycans, upregulates a4/3l-dependent T cell adhesion to VCAM (29) . IL-8, another chemokine, upregulates /32 integrin-dependent neutrophil adhesion to endothelial cells (30) . Another member of the chemokine family, MIP-la, is produced by macrophages, T-lymphocytes, and bone marrow stromal cells (9, 31) . We demonstrate here that IFN-a treatment of stroma results in enhanced MWI-la production, which in turn is capable of directly enhancing /1 integrin-mediated adhesion of CML progenitors. Our results suggest that enhanced production of MIP-la by stroma following IFN-a treatment may, at least in part, be responsible for the enhanced integrin-mediated adhesion of CML progenitors.
The mechanisms through which chemokines mediate these effects are unclear. The receptor for MWP-la and other chemokines has recently been cloned and characterized as a member of the transmembrane G-protein-linked receptor family (32) . Enhanced /32 integrin-mediated adhesion of neutrophils to stroma following IL-8 stimulation is, at least in part, the result of a direct effect of IL-8 on actin polymerization and can be blocked by pertussis toxin (33) . Similar influences on the cytoskeleton may be active in restoring /31 integrin-mediated adhesion of CML progenitors following MWP-la stimulation. Interestingly, recent studies from our laboratory indicate that MIP-la also increases adhesion of normal committed progenitors to marrow stroma (54±1.5% without MWP-la and 63±2% with MIP-la, 100 ng/ml, for 2 h; P < 0.01 ) (34) . The increased adhesion induced by MIP-la is similar to the increased adhesion of normal committed progenitors to IFN-a-treated stroma seen in this study. This suggests that the effect of MIP-la is universal, but more pronounced in CML because of lower baseline integrin function. The hypothesis that MIP-la produced by stroma plays an important role in IFN-a-dependent enhanced adhesion of CML progenitors is strengthened by additional preliminary studies from our group demonstrating that stimulation of stroma with cytokines such as IL-lf3 and TNF-a also increased stromal production of MWP-la (our unpublished observations) and resulted in increased adhesion of CML progenitors. Although multiple alterations in stromal adhesion ligands or cytokines following IFN-a, TNF-a, and IL-lIp exposure (4, 13, (20) (21) (22) (23) could play a part in increased CML progenitor adhe- Figure 5 . IFN-a treatment of stroma results in enhanced production of MIP-la. Stromal layers subcultured in 24-well plates were incubated with lFN-a (10,000 U/ml) for varying periods of time. The MIP-la content of the stromal layers was assayed by detaching IFN-a-treated stromal layers, preparing protein extracts, and then assaying them for MIP-la levels by ELISA (n = 4). Significance levels: ¶P < 0.05.
MIP-la was undetectable in LTBMC media alone. 936 Bhatia et al. MIP-lalpha Concentration (ng/ml) Figure 7 . MIP-la enhances the adhesion of CML CFU-GM to stroma. Adhesion assays were performed between CML DR+ cells (n = 4) and stroma that had not been exposed to LEN-a. MIP-la (0.1-10 ng/ 
